165 related articles for article (PubMed ID: 25003617)
1. Novel peptides suppress VEGFR-3 activity and antagonize VEGFR-3-mediated oncogenic effects.
Chang YW; Su CM; Su YH; Ho YS; Lai HH; Chen HA; Kuo ML; Hung WC; Chen YW; Wu CH; Chen PS; Su JL
Oncotarget; 2014 Jun; 5(11):3823-35. PubMed ID: 25003617
[TBL] [Abstract][Full Text] [Related]
2. Targeting VEGFR-3/-2 signaling pathways with AD0157: a potential strategy against tumor-associated lymphangiogenesis and lymphatic metastases.
García-Caballero M; Paupert J; Blacher S; Van de Velde M; Quesada AR; Medina MA; Noël A
J Hematol Oncol; 2017 Jun; 10(1):122. PubMed ID: 28629427
[TBL] [Abstract][Full Text] [Related]
3. Anlotinib suppresses lymphangiogenesis and lymphatic metastasis in lung adenocarcinoma through a process potentially involving VEGFR-3 signaling.
Qin T; Liu Z; Wang J; Xia J; Liu S; Jia Y; Liu H; Li K
Cancer Biol Med; 2020 Aug; 17(3):753-767. PubMed ID: 32944404
[No Abstract] [Full Text] [Related]
4. Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3.
Kodera Y; Katanasaka Y; Kitamura Y; Tsuda H; Nishio K; Tamura T; Koizumi F
Breast Cancer Res; 2011 Jun; 13(3):R66. PubMed ID: 21693010
[TBL] [Abstract][Full Text] [Related]
5. Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels.
He Y; Rajantie I; Pajusola K; Jeltsch M; Holopainen T; Yla-Herttuala S; Harding T; Jooss K; Takahashi T; Alitalo K
Cancer Res; 2005 Jun; 65(11):4739-46. PubMed ID: 15930292
[TBL] [Abstract][Full Text] [Related]
6. Anti-VEGF-A therapy reduces lymphatic vessel density and expression of VEGFR-3 in an orthotopic breast tumor model.
Whitehurst B; Flister MJ; Bagaitkar J; Volk L; Bivens CM; Pickett B; Castro-Rivera E; Brekken RA; Gerard RD; Ran S
Int J Cancer; 2007 Nov; 121(10):2181-91. PubMed ID: 17597103
[TBL] [Abstract][Full Text] [Related]
7. Stage-specific characterization of the vascular endothelial growth factor axis in prostate cancer: expression of lymphangiogenic markers is associated with advanced-stage disease.
Kaushal V; Mukunyadzi P; Dennis RA; Siegel ER; Johnson DE; Kohli M
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):584-93. PubMed ID: 15701844
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of vascular endothelial growth factor-C and vascular endothelial growth factor receptor 3 in patients with T1 lung adenocarcinoma.
Kojima H; Shijubo N; Yamada G; Ichimiya S; Abe S; Satoh M; Sato N
Cancer; 2005 Oct; 104(8):1668-77. PubMed ID: 16116610
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of VEGFR-3 activation in tumor-draining lymph nodes suppresses the outgrowth of lymph node metastases in the MT-450 syngeneic rat breast cancer model.
Quagliata L; Klusmeier S; Cremers N; Pytowski B; Harvey A; Pettis RJ; Thiele W; Sleeman JP
Clin Exp Metastasis; 2014 Mar; 31(3):351-65. PubMed ID: 24379135
[TBL] [Abstract][Full Text] [Related]
10. Vascular endothelial growth factor C stimulates progression of human gastric cancer via both autocrine and paracrine mechanisms.
Kodama M; Kitadai Y; Tanaka M; Kuwai T; Tanaka S; Oue N; Yasui W; Chayama K
Clin Cancer Res; 2008 Nov; 14(22):7205-14. PubMed ID: 19010837
[TBL] [Abstract][Full Text] [Related]
11. Endothelin-1 induces the transactivation of vascular endothelial growth factor receptor-3 and modulates cell migration and vasculogenic mimicry in melanoma cells.
Spinella F; Caprara V; Di Castro V; Rosanò L; Cianfrocca R; Natali PG; Bagnato A
J Mol Med (Berl); 2013 Mar; 91(3):395-405. PubMed ID: 22965194
[TBL] [Abstract][Full Text] [Related]
12. Suppression of lymphangiogenesis by soluble vascular endothelial growth factor receptor-2 in a mouse lung cancer model.
Maehana S; Nakamura M; Ogawa F; Imai R; Murakami R; Kojima F; Majima M; Kitasato H
Biomed Pharmacother; 2016 Dec; 84():660-665. PubMed ID: 27697638
[TBL] [Abstract][Full Text] [Related]
13. Differential Receptor Binding and Regulatory Mechanisms for the Lymphangiogenic Growth Factors Vascular Endothelial Growth Factor (VEGF)-C and -D.
Davydova N; Harris NC; Roufail S; Paquet-Fifield S; Ishaq M; Streltsov VA; Williams SP; Karnezis T; Stacker SA; Achen MG
J Biol Chem; 2016 Dec; 291(53):27265-27278. PubMed ID: 27852824
[TBL] [Abstract][Full Text] [Related]
14. CPT1A regulates breast cancer-associated lymphangiogenesis via VEGF signaling.
Xiong Y; Liu Z; Zhao X; Ruan S; Zhang X; Wang S; Huang T
Biomed Pharmacother; 2018 Oct; 106():1-7. PubMed ID: 29940537
[TBL] [Abstract][Full Text] [Related]
15. The role of the VEGF-C/VEGFR-3 axis in cancer progression.
Su JL; Yen CJ; Chen PS; Chuang SE; Hong CC; Kuo IH; Chen HY; Hung MC; Kuo ML
Br J Cancer; 2007 Feb; 96(4):541-5. PubMed ID: 17164762
[TBL] [Abstract][Full Text] [Related]
16. Hypoxia-induced epithelial VEGF-C/VEGFR-3 upregulation in carcinoma cell lines.
Simiantonaki N; Jayasinghe C; Michel-Schmidt R; Peters K; Hermanns MI; Kirkpatrick CJ
Int J Oncol; 2008 Mar; 32(3):585-92. PubMed ID: 18292935
[TBL] [Abstract][Full Text] [Related]
17. Collaborative interplay between FGF-2 and VEGF-C promotes lymphangiogenesis and metastasis.
Cao R; Ji H; Feng N; Zhang Y; Yang X; Andersson P; Sun Y; Tritsaris K; Hansen AJ; Dissing S; Cao Y
Proc Natl Acad Sci U S A; 2012 Sep; 109(39):15894-9. PubMed ID: 22967508
[TBL] [Abstract][Full Text] [Related]
18. [Expression and clinical significance of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in non-small cell lung carcinoma].
Lu ZQ; Li HG; Xie DR; Zhang HZ; Shen XM; Zeng YJ; Zeng H
Ai Zheng; 2005 Sep; 24(9):1132-5. PubMed ID: 16159440
[TBL] [Abstract][Full Text] [Related]
19. Tubular network formation by adriamycin-resistant MCF-7 breast cancer cells is closely linked to MMP-9 and VEGFR-2/VEGFR-3 over-expressions.
Karroum A; Mirshahi P; Faussat AM; Therwath A; Mirshahi M; Hatmi M
Eur J Pharmacol; 2012 Jun; 685(1-3):1-7. PubMed ID: 22542663
[TBL] [Abstract][Full Text] [Related]
20. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.
Heckman CA; Holopainen T; Wirzenius M; Keskitalo S; Jeltsch M; Ylä-Herttuala S; Wedge SR; Jürgensmeier JM; Alitalo K
Cancer Res; 2008 Jun; 68(12):4754-62. PubMed ID: 18559522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]